Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics had a very successful 2008, making excellent progress with its development pipeline and reporting a pre-tax profit for the period. The recent start of our Phase III program with microplasmin in patients with back of the eye disease is a major milestone for the Company. Our decision to initiate this pivotal clinical program was driven by the excellent clinical Phase II data that we have generated, combined with our strong financial position. This is the result of the EUR30m upfront payment we received as part of our major strategic licensing deal for TB-403 with Roche, signed in June 2008. We are also making good progress with TB-402, a novel long acting anti-coagulant which we believe has advantages over currently marketed products. As ThromboGenics continues to transform itself into a late-stage development company, I am confident that we have all the tools needed to ensure our corporate success."
For the full report of these results please go to http://www.thrombogenics.com
ThromboGenics is a biotechnology company focused on the discovery and
development of biopharmaceuticals for the treatment of eye disease, vascular
disease and cancer. The Company's lead product Microplasmin is in Phase III
clinical development for the non-surgical treatment of back of the eye
diseases. Microplasmin is also being evaluated in Phase II clinical
development for additional vitreoretinal indications and as a potential
therapy for stroke. ThromboGenics is also developing novel antibody
|SOURCE ThromboGenics NV|
Copyright©2009 PR Newswire.
All rights reserved